jx123 Pokročilý
Počet príspevkov : 155 Registration date : 01.12.2014
| Predmet: Ethidium bromide and UV light revealed the location of the RNA bands Ut november 17, 2015 5:46 am | |
| To investigate the cytotoxic effect of the cisplatinKB9520 combination in non malignant meso thelial cells we treated the mesothelium derived MET5A cells with various concentrations of cisplatin in the pres ence or absence of KB9520. In contrast to the effect in the malignant REN cells KB9520 diminished the KU-0063794 ic50 toxicity of cis platin in the MET5A cells, in part explained by the reduced PARP1 cleavage and increased pAKT levels. It has been de scribed that ER can increase PI3KAKT activity by inter action with the p85 subunit of PI3K. However, if that explains the increased pAKT levels in the MET5A cells needs to be explored in more detail. Conclusions In summary, in this report we have shown that MPM cell proliferation and tumor growth can be effectively suppressed by selective agonist activation of ERB.<br><br> We have also shown that KB9520 acts as a chemosensitizer through activation of ERB Lenalidomide ic50 and that the order of drug ad ministration in combination with cisplatinpemetrexed is essential for the synergistic efficacy observed in vitro and in vivo. KB9520 had no cytotoxic effect in the ERB expressing non malignant mesothelium derived MET5A cells. In contrast, it diminished cisplatin cytotoxicity in these cells. Thus, combination of KB9520 with SOC may increase the sensi tivity of MPM tumors to the SOC regimen in patients and perhaps result in higher response rates, extended progres sion free survival and prolonged overall survival, without adding toxicity. Furthermore, combination with KB9520 may allow milder SOC regimen without loss of anti tumor efficacy and thereby may be come an option for patients that cannot tolerate the standard and more aggressive cisplatinpemetrexed dose regimen.<br><br> Methods Reagents and antibodies The monoclonal antibodies specific for Tubulin, PARP1 and the polyclonal antibody specific for ERB were purchased LY294002 構造 from Santa Cruz Biotechnology. Phospho AKT was from Cell Signaling Technology, anti mouse and anti rabbit IgG peroxidase conjugated antibodies and chemical reagents were from Sigma Aldrich. ECL was from Amersham Pharmacia Biotech. Nitrocellulose membranes and protein assay kit were from Bio Rad. Culture media, sera, antibiotics and LipofectAMINE transfection reagent were from Invitrogen. The ERB selective agonist KB9520 was designed and synthesized by Karo Bio.<br><br> Cell cultures and transfection The epithelioid MPM derived REN cell line, used as the principal experimental model in this investigation, was isolated, characterized and kindly provided by Dr. Albelda S. M. Cells were characterized by BMR Genomics s. r. l. using the PowerPlex 18D System kit. The biphasic MSTO 211H and the mesothelial MET5A cell lines were obtained from the Istituto Scientifico Tumori Cell bank, Genoa, Italy. the MMB cell line derived from pleural effusions of patients with MPM and stabilized in culture. the H2596 cell line produced by Dr. H. I. Pass from surgical specimens derived from patients with resected MPM were kindly provided by Dr. W. Thomas in 2011. Cells were grown in RPMI medium supple mented with 10% FBS, 100 ugml streptomycin and 10 ugml penicillin at 37 C in a humidified environment containing 5% CO2. Mycoplasma infection was excluded by the use of Mycoplasma PlusTM PCR Primer Set kit from Stratagene. | |
|